These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 24857015)

  • 1. The immune space: a concept and template for rationalizing vaccine development.
    Manrique A; Adams E; Barouch DH; Fast P; Graham BS; Kim JH; Kublin JG; McCluskey M; Pantaleo G; Robinson HL; Russell N; Snow W; Johnston MI
    AIDS Res Hum Retroviruses; 2014 Nov; 30(11):1017-22. PubMed ID: 24857015
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vaccine development: From concept to early clinical testing.
    Cunningham AL; Garçon N; Leo O; Friedland LR; Strugnell R; Laupèze B; Doherty M; Stern P
    Vaccine; 2016 Dec; 34(52):6655-6664. PubMed ID: 27769596
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improving influenza vaccine virus selection: report of a WHO informal consultation held at WHO headquarters, Geneva, Switzerland, 14-16 June 2010.
    ; Ampofo WK; Baylor N; Cobey S; Cox NJ; Daves S; Edwards S; Ferguson N; Grohmann G; Hay A; Katz J; Kullabutr K; Lambert L; Levandowski R; Mishra AC; Monto A; Siqueira M; Tashiro M; Waddell AL; Wairagkar N; Wood J; Zambon M; Zhang W
    Influenza Other Respir Viruses; 2012 Mar; 6(2):142-52, e1-5. PubMed ID: 21819547
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vaccine provision: Delivering sustained & widespread use.
    Preiss S; Garçon N; Cunningham AL; Strugnell R; Friedland LR
    Vaccine; 2016 Dec; 34(52):6665-6671. PubMed ID: 27884478
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bridging the gap: need for a data repository to support vaccine prioritization efforts.
    Madhavan G; Phelps C; Sangha K; Levin S; Rappuoli R
    Vaccine; 2015 Jun; 33 Suppl 2(0 2):B34-9. PubMed ID: 26022565
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Focus on Vaccine Development.
    Woodland DL
    Viral Immunol; 2015; 28(6):303. PubMed ID: 26133044
    [No Abstract]   [Full Text] [Related]  

  • 7. Whither vaccines?
    Rodrigues CMC; Pinto MV; Sadarangani M; Plotkin SA
    J Infect; 2017 Jun; 74 Suppl 1():S2-S9. PubMed ID: 28646957
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Statistical methods for down-selection of treatment regimens based on multiple endpoints, with application to HIV vaccine trials.
    Huang Y; Gilbert PB; Fu R; Janes H
    Biostatistics; 2017 Apr; 18(2):230-243. PubMed ID: 27649715
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Novel vaccines against M. tuberculosis].
    Okada M
    Kekkaku; 2006 Dec; 81(12):745-51. PubMed ID: 17240920
    [TBL] [Abstract][Full Text] [Related]  

  • 10. From research to phase III: preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine.
    Guy B; Barrere B; Malinowski C; Saville M; Teyssou R; Lang J
    Vaccine; 2011 Sep; 29(42):7229-41. PubMed ID: 21745521
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improving immunogenicity, efficacy and safety of vaccines through innovation in clinical assay development and trial design: the Phacilitate Vaccine Forum, Washington D.C. 2011.
    Moldovan IR; Tary-Lehmann M
    Hum Vaccin; 2011 Jun; 7(6):610-2. PubMed ID: 21602620
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Profiling immunity to HIV vaccines with systems biology.
    Andersen-Nissen E; Heit A; McElrath MJ
    Curr Opin HIV AIDS; 2012 Jan; 7(1):32-7. PubMed ID: 22134340
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tuberculosis vaccines: progress and challenges.
    Checkley AM; McShane H
    Trends Pharmacol Sci; 2011 Oct; 32(10):601-6. PubMed ID: 21803435
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vaccines for epidemic infections and the role of CEPI.
    Plotkin SA
    Hum Vaccin Immunother; 2017 Dec; 13(12):2755-2762. PubMed ID: 28375764
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Moving candidate vaccines into development from research: lessons from HIV.
    Sullivan M
    Immunol Cell Biol; 2009 Jul; 87(5):366-70. PubMed ID: 19434070
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The current challenges for vaccine development.
    Oyston P; Robinson K
    J Med Microbiol; 2012 Jul; 61(Pt 7):889-894. PubMed ID: 22322337
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systems serology for evaluation of HIV vaccine trials.
    Ackerman ME; Barouch DH; Alter G
    Immunol Rev; 2017 Jan; 275(1):262-270. PubMed ID: 28133810
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.